In recent years, HER2 has also been shown to play an important role in gastric and gastroesophageal adenocarcinoma and in breast cancer and some studies have shown that this indicates a poor prognosis [9, 10] which again can be improved by using trastuzumab. Here, ERBB2 is linked to breast cancer.